Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vericel Corporation - Common Stock (NQ: VCEL )

39.95 -1.15 (-2.79%)
Streaming Delayed Price Updated: 2:03 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vericel Corporation - Common Stock

< Previous 1 2 3 4 Next >
Where Vericel Stands With Analysts
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
What 7 Analyst Ratings Have To Say About Vericel
Via Benzinga
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Beyond The Numbers: 5 Analysts Discuss Vericel Stock
Via Benzinga
Vericel Stock Sees RS Rating Shoot Higher
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79. 
Via Investor's Business Daily
Smaller Cap Biotechs Are In Season: How Are We Doing?
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
Earnings Preview For Vericel
Via Benzinga
The Analyst Verdict: Vericel In The Eyes Of 7 Experts
Via Benzinga
Expert Ratings For Vericel
Via Benzinga
The Latest Analyst Ratings For Vericel
Via Benzinga
Apple To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
A Glimpse Into The Expert Outlook On Vericel Through 4 Analysts
Via Benzinga
Trading SMID Biotech Stocks In A Volatile Market
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
The 3 Highest-Rated Medical Stocks You Can Buy Today
Are you looking for highly-rated medical stocks? These three contenders are offering substantial growth over the long term. 
Via InvestorPlace
Critical Insights From Vericel Analyst Ratings: What You Need To Know
Via Benzinga
Analyst Scoreboard: 5 Ratings For Vericel
Via Benzinga
A Closer Look at 4 Analyst Recommendations For Vericel
Via Benzinga
VCEL Stock Earnings: Vericel Beats EPS, Beats Revenue for Q1 2024
VCEL stock results show that Vericel beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility
Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23. 
Via Talk Markets
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
3 Top Pharma Stocks for Investors Betting on a Biotech Boom
Pharma stocks offer phenomenal returns when their drug gets approved. Here are three stocks that could soar in 2024. 
Via InvestorPlace
HC Wainwright & Co. Maintains Buy Rating for Vericel: Here's What You Need To Know
Via Benzinga
Innovative Burn Care: MediWound Bags Additional DoD Grant For NexoBrid Development
Biopharmaceutical company MediWound Ltd (NASDAQ: MDWD) reported that the U.S. 
Via Benzinga
Analyst Ratings for Vericel
Via Benzinga
Analyst Ratings for Vericel
Via Benzinga
3 Biotech Stocks That Could Boom or Bust by 2025
Biotech stocks are popular with investors because they sometimes provide tremendous rewards. Here are three to buy for a potential payday. 
Via InvestorPlace
3 Strong Buy Stocks Set to Take Off in the Coming Months
These 3 strong buy stocks have industry experts' positive outlook and seal of approval. The only question is, are you in? 
Via InvestorPlace
Earnings Scheduled For November 8, 2023
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter. 
Via Benzinga
Vericel's Short Report: Deep Dive Into Knee-Repair Focused Company's 27 Years of Losses
J Capital Research has released a short idea report on Vericel Corporation (NASDAQ: 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.